These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35094313)

  • 21. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma.
    Lee JI; Chung YJ; Cho BY; Chong S; Seok JW; Park SJ
    Surgery; 2013 Jun; 153(6):828-35. PubMed ID: 23489940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.
    Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F
    J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
    Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
    Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
    Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
    Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact factors of benefiting from initial 131 I ablation in patients with intermediate-risk differentiated thyroid carcinoma: a study based on a re-evaluation of therapeutic response.
    Ren L; Hu Y; Hu Y; Xiao D; Sun J; Zhu B; Zhang C
    Nucl Med Commun; 2024 Mar; 45(3):188-195. PubMed ID: 38165164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response.
    Ahn J; Song E; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Endocrine; 2020 Mar; 67(3):623-629. PubMed ID: 31776976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
    Tresoldi AS; Sburlati LF; Rodari M; Schinkelshoek MS; Perrino M; De Leo S; Montefusco L; Colombo P; Arosio M; Lania AGA; Fugazzola L; Chiti A
    J Endocrinol Invest; 2014 Aug; 37(8):709-714. PubMed ID: 24844565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
    Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
    Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial Thyroglobulin Variation Trend Shortly after Radioiodine Therapy in Poorly to Moderately Differentiated Recurrent Thyroid Cancer.
    Li CX; Hou M; Ren C; Lin YS
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):351-5. PubMed ID: 27469925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
    Mousa U; Yikilmaz AS; Nar A
    Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of Pre-Ablation Stimulated Thyroglobulin in Children and Adolescents with Differentiated Thyroid Cancer.
    Liu L; Zhang X; Tian T; Huang R; Liu B
    Thyroid; 2020 Jul; 30(7):1017-1024. PubMed ID: 31964278
    [No Abstract]   [Full Text] [Related]  

  • 34. The Value of Stimulated Thyroglobulin Before the First Radioactive Iodine Treatment in Metastasis for Differentiated Thyroid Carcinoma.
    Ren L; Zhang C; Shen Y; Mo A; Hu Y; Sun J; Yuan C; Wen W
    Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human thyrotropin-stimulated thyroglobulin level at the time of radioactive iodine ablation is an independent prognostic marker of differentiated thyroid carcinoma in the setting of prophylactic central neck dissection.
    Moon JH; Choi JY; Jeong WJ; Ahn SH; Lee WW; Kim KM; Choi SH; Lim S; Park YJ; Yi KH; Park do J; Jang HC
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):459-65. PubMed ID: 26833982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.
    Kim TY; Kim WB; Kim ES; Ryu JS; Yeo JS; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1440-5. PubMed ID: 15613412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
    Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postoperative stimulated thyroglobulin level and recurrence risk stratification in differentiated thyroid cancer.
    Yang X; Liang J; Li TJ; Yang K; Liang DQ; Yu Z; Lin YS
    Chin Med J (Engl); 2015 Apr; 128(8):1058-64. PubMed ID: 25881600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of postoperative and post-ablative serum thyroglobulin levels in patients with differentiated thyroid cancer.
    Raef H; Malabu UH; Alfadhli E; Al-Hajjaj A; Al-Sobhi S; Rifai A; Al-Nuaim A
    Niger J Med; 2008; 17(4):391-5. PubMed ID: 19048752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.